NCT01678404

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Korea Cancer Center Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with variable differentiation status, which is distributed to a variety of organs. A high response rate and long term survival is possible through surgery or radiation therapy alone in the case of limited disease. However frequent relapse and progression is observed despite of long term survival. The treatment after relapse has not been established yet. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with MZL.

Conditions

• Relapsed or Refractory Marginal Zone B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	131I-rituximab

Timeline

• Start date: 2011-10-01
• Primary completion: 2014-09-01
• Completion: 2016-09-01
• First posted: 2012-09-05
• Last updated: 2012-09-05

Locations

1 site across 1 country: South Korea